Skip to main content
MedPathMedPath Home
Clinical Trials/NCT05797987
NCT05797987
Completed
Not Applicable

Negative Estrogen Receptor (ER) Expression Assessed by 18F-fluoroestradiol Positron Emission Tomography/Computed Tomography (18F-FES PET/CT) in the Metastatic Breast Cancer (MBC) With ER-positive Primary Tumor

Fudan University1 site in 1 country52 target enrollmentDecember 1, 2022
Share to TwitterShare to FacebookShare to LinkedInShare to Reddit
ConditionsBreast Cancer

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
Breast Cancer
Sponsor
Fudan University
Enrollment
52
Locations
1
Primary Endpoint
Progression free survival (PFS)
Status
Completed
Last Updated
2 years ago
OverviewInvestigatorsEligibility CriteriaOutcomesSitesSimilar Trials

Overview

Brief Summary

To investigate the treatment pattern and efficacy of patients with positive primary ER lesion but negative ER expression in MBC using a novel convenient way of 18F-fluoroestradiol positron emission tomography/computed tomography (18F-FES PET/CT).

Registry
clinicaltrials.gov
Start Date
December 1, 2022
End Date
August 1, 2023
Last Updated
2 years ago
Study Type
Observational
Sex
Female

Investigators

Responsible Party
Principal Investigator
Principal Investigator

Biyun Wang, MD

Professor

Fudan University

Eligibility Criteria

Inclusion Criteria

  • •Patients diagnosed with breast cancer (according to International Classification of Diseases 10th Revision) with confirmed metastasis, regardless of being de novo diagnosed or progressed from a non-metastatic stage.
  • •MBC patients who underwent 18F-FES PET/CT at the Fudan University Shanghai Cancer Center between 2010 and 2022
  • •Patients diagnosed with primary ER-positive tumor and who were yet to receive any systemic therapy during the advanced stage

Exclusion Criteria

  • •Patients with incomplete medical records and those diagnosed with secondary primary tumors

Outcomes

Primary Outcomes

Progression free survival (PFS)

Time Frame: 6 weeks

Secondary Outcomes

  • Adverse events(6 weeks)

Study Sites (1)

Loading locations...

Similar Trials

Completed
Not Applicable
Positive ER Expression Assessed by 18F-FES PET/CT in the MBC with ER-negative Primary TumorBreast Cancer
NCT06344767Fudan University19
Not yet recruiting
Not Applicable
Evaluating utility of Oestrogen and Progesterone Receptor biomarkers for prediction of colorectal Cancer
CTRI/2024/05/068054Datta Meghe Institute of Higher Education & Research (DMIHER)
Completed
Phase 2
Palbociclib and FES PETBreast Cancer
NCT02806050University Medical Center Groningen30
Active, not recruiting
Phase 2
Estradiol in Treating Patients With ER Beta Positive, Triple Negative Locally Advanced or Metastatic Breast CancerAdvanced Triple-Negative Breast CarcinomaAnatomic Stage III Breast Cancer AJCC v8Anatomic Stage IV Breast Cancer AJCC v8Metastatic Triple-Negative Breast CarcinomaRecurrent Breast Carcinoma
NCT03941730Mayo Clinic8
Recruiting
Phase 2
STUDY02001740;22SCH740: Estradiol For ER+ Advanced Breast Cancer (ESTHER)Metastatic Breast Cancer
NCT05716516Dartmouth-Hitchcock Medical Center36